Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A unique circulating inhibitor with specificity for coagulation factor X.

M W Lankiewicz1, W R Bell

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2101.

The American Journal of Medicine
|September 1, 1992
PubMed
Summary

An elderly patient experienced severe bleeding due to a rare factor X inhibitor. The anticoagulant disappeared spontaneously, resolving the hemorrhage without specific treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oxidative damage in age-related macular degeneration.

Histology and histopathology·2007
Same author

Urgent reversal of warfarin with prothrombin complex concentrate.

Journal of thrombosis and haemostasis : JTH·2006
Same author

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells.

British journal of cancer·2004
Same author

Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow.

The pharmacogenomics journal·2003
Same author

Role of splenectomy in immune (idiopathic) thrombocytopenic purpura.

Blood reviews·2002
Same author

Thrombotic thrombocytopenic purpura associated with clopidogrel.

The New England journal of medicine·2000

Area of Science:

  • Hematology
  • Internal Medicine
  • Clinical Immunology

Background:

  • Acquired factor deficiencies can lead to serious bleeding complications.
  • Circulating anticoagulants are antibodies that inhibit specific coagulation factors.
  • Factor X inhibitors are rare but can cause life-threatening hemorrhage.

Observation:

  • An 84-year-old woman presented with extensive cutaneous and gastrointestinal bleeding.
  • Laboratory tests showed prolonged prothrombin time and activated partial thromboplastin time.
  • A specific inhibitor targeting factor X was identified in her circulation.

Findings:

  • The patient's bleeding resolved with only supportive care.
  • The factor X inhibitor disappeared spontaneously after approximately 11 months.

Related Experiment Videos

  • This suggests a potential for spontaneous resolution of acquired factor X inhibitors.

    • Implications:

    • Highlights the importance of considering rare factor inhibitors in unexplained bleeding.
    • Demonstrates that acquired factor X inhibitors may resolve without specific immunosuppressive therapy.
    • Provides a case study for understanding the natural history and management of factor X inhibitors.